Ovocentra-M is a medicinal tablet which consists of Myo-Inositol 600mg and Metformin Hydrochloride 500mg. These are the two components that are usually used in the management of metabolic and reproductive concerns related to the polycystic ovary syndrome (PCOS). The combination is developed to support insulin sensitivity and assist in addressing metabolic factors that may contribute to hormonal and menstrual irregularities. Similar combinations that consist of Myo-Inositol 600mg and Metformin Hydrochloride 500mg are used in the PCOS management.
Composition of Ovocentra-M
Each Ovocentra-M tablet consists of:
- Myo-Inositol – 600mg
- Metformin Hydrochloride – 500mg
The exact dosage form and release characteristics should always be verified from the product packaging or prescribing information that is supplied by the manufacturer.
How Ovocentra-M Works?
Ovocentra-M fuses the complementary actions of Myo-Inositol and Metformin Hydrochloride. Myo-Inositol is included in cellular signaling that contains pathways related to the insulin response. It is usually included in formulations that is for women with PCOS specifically where insulin resistance and menstrual or ovulatory irregularities are an issue.
Metformin Hydrochloride is an established medicine that assists in improving the body’s response to insulin and supports proper regulation of blood glucose. It functions initially by lowering the glucose production by the liver and enhancing peripheral insulin sensitivity.
These ingredient when combined together may offer a therapeutic approach for addressing insulin related and reproductive metabolic factors in women with PCOS. Combination products that consists of these strengths are documented for PCOS/PCOD related use.
Uses of Ovocentra-M
Ovocentra M may be advised by healthcare professionals as part of the management of polycystic ovary syndrome (PCOS) specifically when insulin resistance or metabolic disturbances are present. Based on the individual patient’s condition, getting treated with this formulation may support improved insulin sensitivity and assist in menstrual and ovulatory regulation.
PCOS is a complicated hormonal and metabolic condition so treatment should be customised according to symptoms and medical history along with laboratory findings and reproductive goals. Ovocentra-M should therefore be used only as advised by healthcare professional.
Benefits of Ovocentra-M
The combination of Myo-Inositol and Metformin Hydrochloride provides a dual approach to factors usually related to PCOS. Potential therapeutic benefits include:
- Supporting enhanced insulin sensitivity
- Assisting in handling insulin resistance related to PCOS
- Improving menstrual cycle regulation
- Supporting normal ovulatory function
- Identifying metabolic factors related to PCOS
- Providing a combination formulation in a simple tablet dosage form
The suitability and expected advantages can differ from patient to patient and should be accessed by the prescribing physician.
Dosage and Administration
The recommended dose of Ovocentra-M should be determined by the treating physician. Patients should take the medicine exactly as prescribed and should not increase, decrease or discontinue the dose without professional advice.
Metformin-containing medicines can commonly cause gastrointestinal effects such as nausea, diarrhoea, abdominal discomfort or bloating, particularly when treatment is initiated. Taking metformin with food may help improve gastrointestinal tolerance, but patients should follow the specific instructions provided with their prescription.
Safety and Precautions
Ovocentra-M is a prescription medicine and should be used under medical supervision. Patients should inform their doctor about existing medical conditions, allergies and all other medicines or supplements they are taking before beginning treatment.
Particular care may be required in people with kidney or liver problems or other conditions where metformin may not be appropriate. Long-term metformin therapy may also be associated with reduced vitamin B12 levels, making medical monitoring important where clinically indicated.
Ovocentra-M is not intended for self-medication. Always consult a qualified healthcare professional for the appropriate dose, duration and suitability of treatment.
Conclusion
Ovocentra-M, containing Myo-Inositol 600mg + Metformin Hydrochloride 500mg, is a combination pharmaceutical formulation intended to support the medical management of PCOS-related metabolic and reproductive concerns. By combining Myo-Inositol’s role in insulin signalling with Metformin’s established effects on insulin sensitivity and glucose metabolism, the formulation provides a comprehensive therapeutic option when prescribed appropriately.
For the most appropriate treatment plan, patients should consult their gynaecologist, endocrinologist or other qualified healthcare professional before using Ovocentra-M.
